GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (OTCPK:SHPHY) » Definitions » Additional Paid-In Capital

Sihuan Pharmaceutical Holdings Group (Sihuan Pharmaceutical Holdings Group) Additional Paid-In Capital : $543.73 Mil(As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Sihuan Pharmaceutical Holdings Group Additional Paid-In Capital?


Sihuan Pharmaceutical Holdings Group's quarterly additional paid-in capital declined from Dec. 2022 ($556.87 Mil) to Jun. 2023 ($542.12 Mil) but then increased from Jun. 2023 ($542.12 Mil) to Dec. 2023 ($543.73 Mil).

Sihuan Pharmaceutical Holdings Group's annual additional paid-in capital declined from Dec. 2021 ($609.53 Mil) to Dec. 2022 ($556.87 Mil) and declined from Dec. 2022 ($556.87 Mil) to Dec. 2023 ($543.73 Mil).

Sihuan Pharmaceutical Holdings Group Additional Paid-In Capital Historical Data

The historical data trend for Sihuan Pharmaceutical Holdings Group's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sihuan Pharmaceutical Holdings Group Additional Paid-In Capital Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 582.41 624.66 609.53 556.87 543.73

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 609.53 579.86 556.87 542.12 543.73

Sihuan Pharmaceutical Holdings Group Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Sihuan Pharmaceutical Holdings Group Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Sihuan Pharmaceutical Holdings Group's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Sihuan Pharmaceutical Holdings Group (Sihuan Pharmaceutical Holdings Group) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (OTCPK:SHPHY) » Definitions » Additional Paid-In Capital
Comparable Companies
HKSE:01681 HKSE:01349 HKSE:02877 HKSE:06896 HKSE:03613 HKSE:02348 HKSE:01558 HKSE:01061 HKSE:02552 HKSE:02633 XTER:MRK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ NBIX SZSE:000538 NSE:DIVISLAB
Traded in Other Exchanges
00460:Hong Kong
Address
Zhubang 2000 Business Centre, 22nd Floor, Building 4, West Balizhuang, Chaoyang District, Beijing, CHN, 100025
Website
https://www.sihuanpharm.com
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Digestive System, Anti-Infective, metabolism, Respiratory, Neurology, and Others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others to provide non- or minimally invasive medical aesthetics comprehensive solutions; the innovative medicine and other medicine segments; and the generic medicine segment.